DK1148871T3 - Gliclazidholdig matrixtablet med forsinket frisætning af aktivt stof efter oral administrering - Google Patents

Gliclazidholdig matrixtablet med forsinket frisætning af aktivt stof efter oral administrering

Info

Publication number
DK1148871T3
DK1148871T3 DK99947592T DK99947592T DK1148871T3 DK 1148871 T3 DK1148871 T3 DK 1148871T3 DK 99947592 T DK99947592 T DK 99947592T DK 99947592 T DK99947592 T DK 99947592T DK 1148871 T3 DK1148871 T3 DK 1148871T3
Authority
DK
Denmark
Prior art keywords
gliclazide
oral administration
active substance
delayed release
containing matrix
Prior art date
Application number
DK99947592T
Other languages
Danish (da)
English (en)
Inventor
De Barochez Bruno Huet
Patrick Wuthrich
Louis Martin
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9541429&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1148871(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Application granted granted Critical
Publication of DK1148871T3 publication Critical patent/DK1148871T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK99947592T 1999-02-01 1999-10-15 Gliclazidholdig matrixtablet med forsinket frisætning af aktivt stof efter oral administrering DK1148871T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9901082A FR2788981B1 (fr) 1999-02-01 1999-02-01 Comprime matriciel permettant la liberation prolongee de gliclazide apres administration par voie orale
PCT/FR1999/002520 WO2000018373A1 (fr) 1999-02-01 1999-10-15 Comprime matriciel permettant la liberation prolongee de gliclazide apres administration par voie orale

Publications (1)

Publication Number Publication Date
DK1148871T3 true DK1148871T3 (da) 2005-09-19

Family

ID=9541429

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99947592T DK1148871T3 (da) 1999-02-01 1999-10-15 Gliclazidholdig matrixtablet med forsinket frisætning af aktivt stof efter oral administrering

Country Status (37)

Country Link
US (1) US6733782B1 (sk)
EP (1) EP1148871B1 (sk)
JP (2) JP4716465B2 (sk)
KR (1) KR100491600B1 (sk)
CN (1) CN1160061C (sk)
AP (1) AP1243A (sk)
AT (1) ATE296621T1 (sk)
AU (1) AU764516B2 (sk)
BR (1) BR9917012A (sk)
CA (1) CA2273420C (sk)
CZ (1) CZ298196B6 (sk)
DE (1) DE69925639T2 (sk)
DK (1) DK1148871T3 (sk)
EA (1) EA002625B1 (sk)
EE (1) EE05024B1 (sk)
ES (1) ES2241323T3 (sk)
FR (1) FR2788981B1 (sk)
GE (1) GEP20053501B (sk)
HK (1) HK1043049A1 (sk)
HR (1) HRP20010632B1 (sk)
HU (1) HU225693B1 (sk)
ID (1) ID30225A (sk)
IL (2) IL144246A0 (sk)
ME (1) ME00436B (sk)
NO (1) NO329951B1 (sk)
NZ (1) NZ512878A (sk)
OA (1) OA11756A (sk)
PL (1) PL194505B1 (sk)
PT (1) PT1148871E (sk)
RS (1) RS50121B (sk)
SA (1) SA00210446B1 (sk)
SK (1) SK285209B6 (sk)
TR (1) TR200102002T2 (sk)
UA (1) UA68414C2 (sk)
WO (1) WO2000018373A1 (sk)
YU (1) YU53101A (sk)
ZA (1) ZA200106305B (sk)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP1243A (en) * 1999-02-01 2004-02-02 Servier Lab Core tablet for controlled release of gliclazide after oral administration.
SE0200539D0 (sv) * 2002-02-25 2002-02-25 Metcon Medicin Ab Granulation process and starch granulate
CN100391459C (zh) * 2003-05-26 2008-06-04 沈阳药科大学 甲磺酸多沙唑嗪缓释制剂
CN1294908C (zh) * 2003-06-08 2007-01-17 安徽省医药科技实业公司 口服格列齐特缓释制剂
JP2007534704A (ja) * 2004-04-29 2007-11-29 美時化学製薬股▲ふん▼有限公司 経口徐放性錠剤組成物およびその製造方法
CN100413491C (zh) * 2004-06-14 2008-08-27 北京德众万全药物技术开发有限公司 一种难溶性药物的控释制剂
EP1827453A1 (en) * 2004-12-06 2007-09-05 Themis Laboratories Private Limited Sulfonylurea compositions and a process for its preparation
WO2007055329A1 (ja) * 2005-11-11 2007-05-18 Asahi Kasei Chemicals Corporation 徐放性固形製剤
US20080286343A1 (en) * 2007-05-16 2008-11-20 Dzenana Cengic Solid form
TR200704897A1 (tr) 2007-07-13 2009-02-23 Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� Uzatılmış salım sağlayan gliklazid formülasyonları@
TR200708938A2 (tr) * 2007-12-26 2008-11-21 Ali̇ Rai̇f İlaç Sanayi̇ Ve Ti̇caret A.Ş. Uzatılmış salım sağlayan gliklazid tablet
ITFI20080016A1 (it) * 2008-02-05 2009-08-06 Valpharma Sa Formulazioni farmaceutiche orali contenenti gliclazide.
FR2928836B1 (fr) * 2008-03-21 2011-08-26 Servier Lab Forme galenique secable permettant une liberation modifiee du principe actif
WO2009140279A2 (en) * 2008-05-12 2009-11-19 Concert Pharmaceuticals, Inc. Sulfonyl urea compounds
EP2181705A1 (en) 2008-10-31 2010-05-05 Disphar International B.V. Sustained-release formulation of gliclazide
EP2403486A1 (en) * 2009-03-03 2012-01-11 XenoPort, Inc. Sustained release oral dosage forms of an r-baclofen prodrug
AR081935A1 (es) 2010-06-16 2012-10-31 Teijin Pharma Ltd Tableta con nucleo recubierto de liberacion controlada
EP2468268B1 (en) 2010-12-21 2017-12-13 Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi Combination composition of vildagliptin and gliclazide
TR201107482A1 (tr) 2010-12-21 2012-07-23 Sanovel İlaç San.Ve Ti̇c.A.Ş. Vildagliptin ve gliklazidin iki tabakalı kombinasyon kompozisyonu.
TR201103946A1 (tr) 2011-04-22 2012-11-21 Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Kontrollü salım sağlayan gliklazid formülasyonları.
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
WO2013124832A2 (en) 2012-02-24 2013-08-29 Ranbaxy Laboratories Limited Stabilized controlled-release pharmaceutical composition comprising gliclazide
EP2958548A1 (en) 2013-02-19 2015-12-30 Sanovel Ilac Sanayi ve Ticaret A.S. A production process for gliclazide formulations
ITFI20130184A1 (it) * 2013-08-01 2015-02-02 Valpharma Internat S P A Una formulazione farmaceutica di gliclazide a rilascio modificato, somministrabile per via orale, e suo metodo di produzione.
ITMI20132065A1 (it) * 2013-12-11 2015-06-12 Farmatron Ltd Sistemi terapeutici a rilascio modificato per la somministrazione orale di curcumina nel trattamento delle malattie intestinali
ES2732925T3 (es) 2014-07-18 2019-11-26 Sanofi Sa Método para predecir el resultado de un tratamiento con aflibercept de un paciente que se sospecha que padece un cáncer
WO2016042568A1 (en) * 2014-09-16 2016-03-24 Suresh Pareek Extended release formulation of gliclazide
CN111329841B (zh) * 2020-03-04 2021-11-19 山东鲁抗医药集团赛特有限责任公司 格列齐特缓释片及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1449404A (en) * 1973-03-30 1976-09-15 Science Union & Cie N-arylsulphonyl urea derivatives
US4056623A (en) * 1975-03-05 1977-11-01 Science Union Et Cie, Societe Francaise De Recherche Medicale Methods of treating animals suffering from hyperlipidemia using certain N-phenyl sulphonyl-N'-(3-azabicycloalkyl) ureas
US5057321A (en) * 1990-06-13 1991-10-15 Alza Corporation Dosage form comprising drug and maltodextrin
IT1246188B (it) * 1990-07-27 1994-11-16 Resa Farma Procedimento per la preparazione di composizioni farmaceutiche aventi aumentata velocita' di dissoluzione della sostanza attiva e composizioni ottenute.
DE4336159A1 (de) * 1993-10-22 1995-04-27 Kurt Heinz Prof Dr Bauer Hochwirksame, den Wirkstoff schnell oder kontrolliert freisetzende Zubereitungsformen von Sulfonylharnstoffen und Verfahren zu deren Herstellung
US6056977A (en) * 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
AP1243A (en) * 1999-02-01 2004-02-02 Servier Lab Core tablet for controlled release of gliclazide after oral administration.

Also Published As

Publication number Publication date
JP2008179649A (ja) 2008-08-07
IL144246A0 (en) 2002-05-23
SK285209B6 (sk) 2006-08-03
FR2788981A1 (fr) 2000-08-04
EE05024B1 (et) 2008-06-16
PL194505B1 (pl) 2007-06-29
HUP0105365A3 (en) 2002-11-28
PL356707A1 (en) 2004-06-28
EP1148871A1 (fr) 2001-10-31
FR2788981B1 (fr) 2002-05-17
YU53101A (sh) 2004-05-12
EP1148871B1 (fr) 2005-06-01
JP2002525310A (ja) 2002-08-13
HK1043049A1 (en) 2002-09-06
CN1160061C (zh) 2004-08-04
CN1342068A (zh) 2002-03-27
PT1148871E (pt) 2005-08-31
NZ512878A (en) 2002-05-31
ID30225A (id) 2001-11-15
EA200100827A1 (ru) 2002-02-28
AP2001002212A0 (en) 2001-09-30
HUP0105365A2 (hu) 2002-04-29
DE69925639T2 (de) 2006-04-27
EA002625B1 (ru) 2002-06-27
EE200100398A (et) 2002-10-15
HU225693B1 (en) 2007-06-28
ATE296621T1 (de) 2005-06-15
OA11756A (en) 2005-07-19
HRP20010632A2 (en) 2005-02-28
CA2273420C (fr) 2002-07-09
ZA200106305B (en) 2002-07-31
DE69925639D1 (de) 2005-07-07
KR100491600B1 (ko) 2005-05-27
TR200102002T2 (tr) 2002-01-21
HRP20010632B1 (en) 2006-02-28
NO329951B1 (no) 2011-01-31
WO2000018373A1 (fr) 2000-04-06
JP4716465B2 (ja) 2011-07-06
AP1243A (en) 2004-02-02
US6733782B1 (en) 2004-05-11
UA68414C2 (en) 2004-08-16
ME00436B (me) 2011-10-10
NO20013757D0 (no) 2001-07-31
CA2273420A1 (fr) 2000-08-01
KR20010093307A (ko) 2001-10-27
NO20013757L (no) 2001-08-09
RS50121B (sr) 2009-03-25
CZ298196B6 (cs) 2007-07-18
SA00210446B1 (ar) 2006-10-11
AU6098299A (en) 2000-04-17
BR9917012A (pt) 2002-04-16
IL144246A (en) 2006-12-10
GEP20053501B (en) 2005-05-10
CZ20012661A3 (cs) 2001-11-14
AU764516B2 (en) 2003-08-21
ES2241323T3 (es) 2005-10-16
SK10952001A3 (sk) 2001-12-03

Similar Documents

Publication Publication Date Title
DK1148871T3 (da) Gliclazidholdig matrixtablet med forsinket frisætning af aktivt stof efter oral administrering
DK1207867T3 (da) Retarderede, orale farmaceutiske indgivelsesformer med tramadol
DK1043976T3 (da) Oral farmaceutisk doseringsform med langvarig frigivelse
NO20006504L (no) Stabilt oralt doseringspreparat med langvarig frigivelse
DK1204410T3 (da) Farmaceutisk doseringsform med flere komponenter
FI4823U1 (fi) Muunnetulla tavalla vapauttava lääkeformulaatio
DK1674084T3 (da) Forlænget frigivelse af oral dosissammensætning
DK1439829T3 (da) Lægemiddel indeholdende 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol med forsinket frigivelse af det aktive stof
DK1020185T3 (da) Opioide analgetika med kontrolleret frigivelse af aktivt stoft
DK1501485T3 (da) Tablet med höjt indhold af aktivt stof
NO20022970L (no) Hydrogel-drevet medikamentdoseringsform
AR028372A1 (es) Dispositivos de administracion de drogas de liberacion sostenida, metodos de uso y metodos de fabricacion de los mismos
SI1435915T1 (sl) Oralne dozirne oblike za propiverin ali njegove farmacevtsko sprejemljive soli s podaljšanim sproščanjem učinkovine
PT1221918E (pt) Administracao de drogas sub-tenon
DK1158992T3 (da) Anvendelse af xenon til fremstilling af et farmaceutisk præparat til behandling af neurointoksikationer
NO20014035D0 (no) System for oral administrasjon av medikament
DE60020501D1 (de) Trimetazidinhaltige Matrixtablette zur verlängerten Wirkstofffreisetzung nach oraler Gabe
NO20014738D0 (no) Tolperisonholdig farmasöytisk preparat for oral administrering
NO20001375L (no) Legemiddelformulering med kontrollert virkestoffrigivning
FI20000780A (fi) Peroraalinen lääkemuoto lääkeaineen hallituksi vapauttamiseksi
DK1071397T3 (da) Levosimendan-holdige lægemidler til oral indgivelse med kontrolleret frisætning af det aktive middel
IS7383A (is) Skammtaform með stýrða lyflosun til inngjafar
EE200300045A (et) Kristalne ravimaine
DK0979069T3 (da) Fremgangsmåde til fremstilling af peroralt anvendelige faste lægemiddelformer med styret afgivelse af aktivt stof
DE10081277D2 (de) Kapsel mit kontrollierter Wirkstofffreisetzung